Article info

Download PDFPDF

Original research
Variation in the estimated costs of pivotal clinical benefit trials supporting the US approval of new therapeutic agents, 2015–2017: a cross-sectional study

Authors

  • Thomas J Moore Institute for Safe Medication Practices, Alexandria, Virginia, USADepartment of Epidemiology, The George Washington University Milken Institute School of Public Health, Washington, DC, USA PubMed articlesGoogle scholar articles
  • James Heyward Center for Drug Safety and Effectiveness, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Gerard Anderson Department of Heath Policy and Management, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • G Caleb Alexander Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USADivision of General Internal Medicine, Johns Hopkins Medicine, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Thomas J Moore; tmoore{at}ismp.org
View Full Text

Citation

Moore TJ, Heyward J, Anderson G, et al
Variation in the estimated costs of pivotal clinical benefit trials supporting the US approval of new therapeutic agents, 2015–2017: a cross-sectional study

Publication history

  • Received March 26, 2020
  • Revised May 8, 2020
  • Accepted May 11, 2020
  • First published June 11, 2020.
Online issue publication 
June 11, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.